source
- Beacon Therapeutics reports positive pivotal trial results for X-linked retinitis pigmentosa gene therapyBeacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP) met the primary endpoint in a phase 2/3 Vista study. The trial enrolled 85 male patients and compared two dose lev…
- Jehovah's Witnesses ease ban, permitting blood-derived products while still forbidding whole-blood transfusionsThe religious group announced a revision to its long-standing medical policy, now allowing members to receive products derived from donated blood. The new guidance says individuals may accept plas…